EchoSolv AS vs uOmnispace.MI
AI Verdict
Choose EchoSolv AS if…
Choose EchoSolv AS if your primary goal is to rapidly and accurately identify patients at high risk for severe aortic stenosis using AI-powered analysis of existing echocardiogram measurements. This tool is ideal for providing consistent severe AS probability and guideline checks, enhancing clinical decision support, and prioritizing studies for closer review within existing PACS workflows without requiring EMR integration.
View EchoSolv AS →Choose uOmnispace.MI if…
Choose uOmnispace.MI if you require comprehensive 2D and 3D medical image viewing, advanced AI-enhanced segmentation, and quantitative analysis across multiple modalities such as PET, CT, MR, and SPECT. This software is best suited for detailed diagnostic and treatment planning in complex cases across oncology, neurology, and cardiology, especially when multi-user access and robust image manipulation capabilities are essential for in-depth analysis.
View uOmnispace.MI →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | EchoSolv AS | uOmnispace.MI |
|---|---|---|
| Deployment | Cloud-based | Unknown |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Unknown |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
EchoSolv ASEchoSolv AS is designed for seamless integration into existing PACS workflows without requiring EMR integration, and boasts ultra-fast risk detection under three seconds. This focus on minimal disruption and speed suggests a higher degree of immediate usability for clinicians. In contrast, uOmnispace.MI, while flexible, presents as a broader and potentially more complex imaging workstation.
Clinical Value
EchoSolv ASEchoSolv AS is an FDA-cleared, AI-powered clinical decision support tool specifically for severe aortic stenosis, demonstrating near-perfect accuracy and outperforming traditional clinical interpretation in studies. Its focused application addresses a critical clinical need with high impact. While uOmnispace.MI is also FDA-cleared and offers broad AI-enhanced imaging analysis across multiple specialties, its value is less targeted than EchoSolv AS's specific decision support.
Pricing & Value
EchoSolv ASEchoSolv AS operates on a subscription-based model and has identified a miscellaneous reimbursement code (93799) that is expected to provide US$100-US$150 per use, offering a clear pathway for financial value to adopting institutions. uOmnispace.MI's pricing is listed as 'contact vendor,' and no public information regarding its reimbursement strategy or cost transparency is available.
Enterprise Readiness
uOmnispace.MIBoth tools are HIPAA compliant, have BAA, and FDA clearance, indicating foundational enterprise readiness. However, uOmnispace.MI offers superior deployment flexibility, supporting SaaS, on-premise, and hybrid models, and is compatible with off-the-shelf PCs. This adaptability caters to a wider range of enterprise IT infrastructures and preferences, giving it an edge in readiness.
Innovation
EchoSolv ASEchoSolv AS demonstrates distinct innovation through its 'measurement-based AI' approach, analyzing numerical echocardiographic data rather than raw images, and notably avoiding LVOT measurements to detect severe AS. This addresses a specific clinical challenge with a novel technical solution. While uOmnispace.MI offers advanced AI-enhanced segmentation and multi-modal analysis, these are more broadly established in the medical imaging field.
Support & Docs
TieBoth companies indicate the availability of support channels and documentation. Echo IQ mentions 'Feedback & Support' and a 'Clinician user manual' for EchoSolv AS. Similarly, United Imaging's website includes a 'Support' section for uOmnispace.MI, and FDA documents detail various software documentation. However, neither provides specific details on the scope, responsiveness, or public accessibility of their comprehensive user support or documentation, leading to a tie.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | EchoSolv AS | uOmnispace.MI |
|---|---|---|
| Name | EchoSolv AS | uOmnispace.MI |
| Company | Echo IQ | Shanghai United Imaging Healthcare Co. |
| Description | EchoSolv AS is an FDA-cleared, AI-powered clinical decision support platform by Echo IQ that analyzes echocardiograms to identify patients at risk for severe aortic stenosis with high accuracy and efficiency, integrating into existing workflows. | uOmnispace.MI is an advanced medical imaging software by Shanghai United Imaging Healthcare Co., Ltd. that provides comprehensive 2D and 3D viewing, AI-enhanced segmentation, and analysis tools for PET, CT, MR, and SPECT images, supporting clinical workflows in oncology, neurology, and cardiology. |
| Primary Clinical Focus | Severe Aortic Stenosis | Oncology, Neurology, Cardiology (across PET, CT, MR, SPECT images) |
| Key Feature 1 | AI-powered clinical decision support for severe aortic stenosis probability | 2D and 3D medical image viewing |
| Key Feature 2 | Consistent severe AS probability and guideline check from measurements | Annotation and measurement tools |
| Key Feature 3 | Second reader support to help prioritize studies for closer review | Manual and automatic segmentation (including AI-based rib extraction) |
Videos
Demos, reviews, and walkthroughs featuring EchoSolv AS and uOmnispace.MI.